Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

Trial Details

NCT ID
NCT07155226
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • AZD3632
  • Posaconazole
Locations (sample)
  • Decatur, Illinois, United States|39.84031,-88.9548
  • New York, New York, United States|40.71427,-74.00597
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Core criteria:
  • Adequate organ function.
  • Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for th…
  • Advanced haematologic malignancy - a) for dose escalation - diagnosis of acute leukemia or myelodysplastic neoplasia (MDS) and harbouring one of th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →